CoChat

The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis

Amini-Salehi, Ehsan, Hassanipour, Soheil, Keivanlou, Mohammad-Hossein, Shahdkar, Milad, Orang Goorabzarmakhi, Mahdi, Vakilpour, Azin, Joukar, Farahnaz, Hashemi, Mohammad, Sattari, Nazila, Javid, Mohammadreza, Mansour-Ghanaei, Fariborz · 2024 · Nutrition Reviews

The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index.

Abstract

Context: Nonalcoholic fatty liver disease (NAFLD) is considered the leading cause of chronic liver disease worldwide. To date, no confirmed medication is available for the treatment of NAFLD. Previous studies showed the promising effects of gut microbiome–targeted therapies; however, the results were controversial and the strength of the evidence and their clinical significance remained unclear. Objectives: This umbrella study summarizes the results of meta-analyses investigating the effects of probiotics, prebiotics, and synbiotics on liver enzymes in the NAFLD population. Data Source: A comprehensive search of the PubMed, Scopus, Web of Science, and Cochrane Library databases was done up to December 20, 2022, to find meta-analyses on randomized control trials reporting the effects of gut microbial therapy on patients with NAFLD. Data Extraction: Two independent investigators extracted data on the characteristics of meta-analyses, and any discrepancies were resolved by a third researcher. The AMSTAR2 checklist was used for evaluating the quality of studies. Data Analysis: A final total of 15 studies were included in the analysis. Results showed that microbiome-targeted therapies could significantly reduce levels of alanine aminotransferase (ALT; effect size [ES], −10.21; 95% confidence interval [CI], −13.29, −7.14; P < 0.001), aspartate aminotransferase (AST; ES, −8.86; 95%CI, −11.39, −6.32; P < 0.001), and γ-glutamyltransferase (ES, −5.56; 95%CI, −7.92, −3.31; P < 0.001) in patients with NAFLD. Results of subgroup analysis based on intervention showed probiotics could significantly reduce levels of AST (ES, −8.69; 95%CI, −11.01, −6.37; P < 0.001) and ALT (ES, −9.82; 95%CI, −11.59, −8.05; P < 0.001). Synbiotics could significantly reduce levels of AST (ES, −11.40; 95%CI, −13.91, −8.88; P < 0.001) and ALT (ES, −11.87; 95%CI, −13.80, −9.95; P < 0.001). Prebiotics had no significant effects on AST and ALT levels (ES, −2.96; 95%CI, −8.12, 2.18, P = 0.259; and ES, −4.69; 95%CI, −13.53, 4.15, P = 0.299, respectively). Conclusion: Gut microbiome–targeted therapies could be a promising therapeutic approach in the improvement of hepatic damage in patients with NAFLD. However, more studies are needed to better determine the best bacterial strains, duration of treatment, and optimum dosage of gut microbiome–targeted therapies in the treatment of the NAFLD population. Systematic Review Registration: PROSPERO registration no. CRD42022346998.

Overview

Integrity signals

Registry

Crossref · 10.1093/nutrit/nuad086

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 95 references

Cited by

See all 51

Metadata

Authors
Amini-Salehi, E., Hassanipour, S., Keivanlou, M.-H., Shahdkar, M., Orang Goorabzarmakhi, M., Vakilpour, A., Joukar, F., Hashemi, M., Sattari, N., Javid, M., & Mansour-Ghanaei, F.
Affiliations
  • Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht, Iran
  • Guilan University of Medical Sciences (IR)
  • School of Medicine, Guilan University of Medical Sciences , Rasht, Iran
  • Hormozgan University of Medical Sciences (IR)
Venue
Nutrition Reviews
Published
2023-08-07
Volume
82
Issue
6
Pages
815-830
ISSN
  • 0029-6643 (ISSN-L)
  • 1753-4887
OpenAlex
W4385621532
Cited by
42
References
96
Citations by year
2026: 8 · 2025: 18 · 2024: 16
FWCI
1.63
Type
journal article
Language
en
Open access
closed
Locations
  • Nutrition Reviews (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
non-alcoholic fatty liver disease, probiotics, prebiotics, synbiotics, liver enzymes, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, NAFLD treatment, evidence quality assessment, AMSTAR 2, subgroup analysis
MeSH terms
Gastrointestinal Microbiome, Alanine Transaminase, Aspartate Aminotransferases, Humans, Liver, Probiotics, Prebiotics, Synbiotics, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis. https://app.cochat.ai/papers/10.1093/nutrit/nuad086
The paper
Amini-Salehi, E., Hassanipour, S., Keivanlou, M.-H., Shahdkar, M., Orang Goorabzarmakhi, M., Vakilpour, A., Joukar, F., Hashemi, M., Sattari, N., Javid, M., & Mansour-Ghanaei, F. (2024). The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis. Nutrition Reviews. https://doi.org/10.1093/nutrit/nuad086

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.